Develops antibody-drug conjugates for metastatic prostate cancer.
Jun 2026Revenue $4.62M/yrExpenses $54.9M/yr
No trendCash runway ≈ 2.4 years from Jun 2026
Figures by year
When will Kyntra Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.62M and expenses $54.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.44M | $52.3M | −$45.9M |
| Dec 2024 | $29.6M | $180M | −$150M |
| Dec 2023 | $46.8M | $370M | −$323M |
| Dec 2022 | $141M | $442M | −$301M |
| Dec 2021 | $235M | $524M | −$289M |
| Dec 2020 | $176M | $368M | −$192M |
| Dec 2019 | $257M | $346M | −$89.3M |
| Dec 2018 | $213M | $300M | −$86.7M |
| Dec 2017 | $131M | $248M | −$117M |
| Dec 2016 | $183M | $233M | −$50.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.